BCR and Familial prostate cancer: In the multivariate Cox model, after adjustment for clinicopathological predictors, TNFRSF13B rs4792800 was independently associated with BCR (HR = 1.78, 95% CI = 1.16–2.71, p = 0.008; Table 3), reinforcing the importance of TNFRSF13B rs4792800 in prostate cancer progression.